3-cyclopentyl-N-[1-(2-hydroxy-2-methyl-propyl)-1H-pyrazol-3-yl]-2-[4-(2-methoxy-phenoxy)-6-oxo-6H-pyridazin-1-yl]-propionamide | 1191451-79-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-cyclopentyl-N-[1-(2-hydroxy-2-methyl-propyl)-1H-pyrazol-3-yl]-2-[4-(2-methoxy-phenoxy)-6-oxo-6H-pyridazin-1-yl]-propionamide
• 英文别名: 3-cyclopentyl-N-[1-(2-hydroxy-2-methylpropyl)pyrazol-3-yl]-2-[4-(2-methoxyphenoxy)-6-oxopyridazin-1-yl]propanamide
• CAS: 1191451-79-2
• 化学式: C₂₆H₃₃N₅O₅
• 分子量: 495.579
• InChiKey: QNVDVGCJKHSBPO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  36
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  118
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  3-cyclopentyl-2-[4-(2-methoxy-phenoxy)-6-oxo-6H-pyridazin-1-yl]-propionic acid 、 1-(3-aminopyrazol-1-yl)-2-methyl-propan-2-ol 以afforded 3-cyclopentyl-N-[1-(2-hydroxy-2-methyl-propyl)-1H-pyrazol-3-yl]-2-[4-(2-methoxy-phenoxy)-6-oxo-6H-pyridazin-1-yl]-propionamide as a white solid (83.8 mg, 65%)的产率得到3-cyclopentyl-N-[1-(2-hydroxy-2-methyl-propyl)-1H-pyrazol-3-yl]-2-[4-(2-methoxy-phenoxy)-6-oxo-6H-pyridazin-1-yl]-propionamide
  参考文献：
  名称：

  PYRIDAZINONE GLUCOKINASE ACTIVATORS

  摘要：

  本文提供了公式（I）的化合物，以及其药学上可接受的盐，其中取代基如规范所披露。这些化合物和含有它们的药物组合物，对于治疗代谢性疾病和疾病非常有用，例如2型糖尿病。

  公开号：

  US20090264434A1

文献信息

• Methods and compositions for modulating serum cortisol levels
  申请人：Lecanu Laurent

  公开号：US20060194815A1

  公开（公告）日：2006-08-31

  The present invention relates to cortisol-modulating compounds, including but not limited to benzamide and benzoic acid derivatives such as procaine and procaine derivatives, utilized in compositions and methods for treating cortisol-mediated disorders, including but not limited to age-related depression, hypertension, Alzheimer's disease, and acquired immunodeficiency syndrome.

  本发明涉及皮质醇调节化合物，包括但不限于苯甲酰胺和苯甲酸衍生物，如普鲁卡因和普鲁卡因衍生物，用于治疗皮质醇介导的疾病的组合物和方法，包括但不限于年龄相关性抑郁症，高血压，阿尔茨海默病和获得性免疫缺陷综合症。
• Benzamide compounds
  申请人：Papadopoulos Vassilios

  公开号：US20060194814A1

  公开（公告）日：2006-08-31

  The invention provides a therapeutic method for preventing or treating a pathological condition or symptom in a mammal, such as a human, wherein the infectivity of a pathogen such as a retrovirus toward mammalian cells is implicated and inhibition of its infectivity is desired comprising administering to a mammal in need of such therapy, an effective amount of an N-benzamide derivative of a piperazinyl amide of an amino acid thereof that inhibits pathogenic infectivity, including pharmaceutically acceptable salts thereof. The invention also provides a therapeutic method for preventing or treating a neuropathological condition or symptom in a mammal, such as human, comprising administering to a mammal in need of such therapy, an effective amount of an N-benzamide derivative of a piperazinyl amide of an amino acid thereof, including pharmaceutically acceptable salts thereof.

  本发明提供了一种治疗方法，用于预防或治疗哺乳动物（如人类）中的病理状况或症状，其中涉及病原体（如逆转录病毒）对哺乳动物细胞的感染性，并且希望抑制其感染性，包括向需要该疗法的哺乳动物施用有效量的N-苯甲酰基衍生物的哌嗪酰胺及其氨基酸，其抑制了病原体的感染性，包括其药物可接受的盐。本发明还提供了一种治疗方法，用于预防或治疗哺乳动物（如人类）中的神经病理状况或症状，包括向需要该疗法的哺乳动物施用有效量的N-苯甲酰基衍生物的哌嗪酰胺及其氨基酸，包括其药物可接受的盐。
• Pyridazinone glucokinase activators
  申请人：Hoffmann-La Roche Inc.

  公开号：US08258134B2

  公开（公告）日：2012-09-04

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

  本文提供了公式（I）化合物及其药学上可接受的盐，其中取代基如规范中所述。这些化合物及含有它们的药物组合物，可用于治疗代谢性疾病和紊乱，例如2型糖尿病。
• Use of (4-Alkylpiperazinyl)(phenyl) methanones in the treatment of alzheimer's disease
  申请人：Lecanu Laurent

  公开号：US20090197891A1

  公开（公告）日：2009-08-06

  The invention provides a therapeutic method for treating at least one symptom of Alzheimer's disease in a mammal, such as a human, wherein the toxicity of a pathogen of β amyloid peptide mammalian cells is implicated and inhibition of the subsequently-induced pathological pathways is desired comprising administering to a mammal in need of such therapy, an effective amount of a benzoylpiperazine derivative, including pharmaceutically acceptable salts thereof.

  本发明提供了一种治疗哺乳动物，如人类阿尔茨海默病至少一种症状的治疗方法，其中涉及β淀粉样肽哺乳动物细胞的病原体毒性，并且希望抑制随后诱导的病理途径，包括向需要此类治疗的哺乳动物施用有效量的苯甲酰哌嗪衍生物，包括其药学上可接受的盐。
• Neuroprotective benzoate and benzamide compounds
  申请人：Lecanu Laurent

  公开号：US20060167108A1

  公开（公告）日：2006-07-27

  The invention provides a therapeutic method for treating at least one symptom of a neurological disorder or disease such as Alzheimer's disease in a mammal, such as a human, wherein the toxicity of a pathogen of β amyloid peptide and/or glutamate in mammalian cells is implicated and inhibition of the subsequently-induced pathological pathways is desired comprising administering to a mammal in need of such therapy, an effective amount of an N-arylamide or an (N-aminoalkyl)benzamide, including pharmaceutically acceptable salts thereof.

  本发明提供了一种治疗方法，用于治疗哺乳动物（如人类）的神经紊乱或疾病（如阿尔茨海默病）的至少一种症状、其中牵涉到哺乳动物细胞中β淀粉样肽和/或谷氨酸的病原体的毒性，并希望抑制随后诱发的病理途径，包括向需要此类治疗的哺乳动物施用有效量的N-芳酰胺或（N-氨基烷基）苯甲酰胺，包括其药学上可接受的盐。